Tivozanib (Fotivda)

Targeted Therapy · Approved since 2021

US Off-label EU med_ema_approved ES med_spain_not_funded med_crc_off_label Oral 4 Clinical Trials
VEGFR-1 VEGFR-2 VEGFR-3

Description

Tivozanib (AV-951) is an oral multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3). In colorectal cancer, tivozanib has been evaluated in combination with standard chemotherapy regimens including FOLFOX and capecitabine for patients with metastatic disease. The drug aims to inhibit tumor angiogenesis while chemotherapy targets cancer cells directly. Tivozanib is currently approved for advanced renal cell carcinoma but remains in clinical development for colorectal cancer applications.

Mechanism of Action

Tivozanib selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinases, which are critical for tumor blood vessel formation and growth. By blocking these receptors, the drug disrupts the vascular endothelial growth factor signaling pathway, leading to reduced tumor angiogenesis and potentially enhanced sensitivity to concurrent chemotherapy.

Molecular Targets

Side Effects

Hypertension Fatigue Diarrhea Decreased appetite Nausea Dysphonia Hypothyroidism Cough

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT01478594 med_phase_prefix2
Archived
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
United States, Australia, Austria, Belgium, Canada, Czechia, Finland, Hungary, I
NCT01306630 med_phase_prefix1
Archived
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
United States
NCT01058655 med_phase_prefix1
Archived
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
United States
NCT00660153 med_phase_prefix1
Archived
Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
Netherlands

Quick Info

Brand NameFotivda
CategoryTargeted Therapy
US StatusOff-label
EU Estado EMAmed_ema_approved
ES Acceso Españamed_spain_not_funded med_crc_off_label
AdministrationOral
Year Approved2021
Clinical Trials4
View Clinical Trials Back to Drug Glossary

Related Medications

Fruquintinib
Targeted Therapy
55 trials
Apatinib
Targeted Therapy
11 trials
Ramucirumab
Immunotherapy
10 trials
Sorafenib
Targeted Therapy
10 trials
Sunitinib
Targeted Therapy
9 trials
Vandetanib
Targeted Therapy
7 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.